SCHEMBL2700832

SCHEMBL2700832

COc1cc(NC(=O)O)cnc1N1CCC[C@@]2(CCN(C3CCC(O)CC3)C2=O)C1

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JAK2 O60674 2/20 0.33
JAK1 P23458 2/20 0.33
TYK2 P29597 2/20 0.33
JAK3 P52333 1/20 0.33
MAPT P10636 1/20 0.33
PLK1 P53350 2/20 0.33
TTK P33981 2/20 0.33
AADAT Q8N5Z0 2/20 0.33
OPRK1 P41145 2/20 0.33
PRKDC P78527 2/20 0.33
PTPN11 Q06124 1/20 0.33
PDE5A O76074 2/20 0.32
PIK3CA P42336 1/20 0.32
MTOR P42345 1/20 0.32
HCRTR1 O43613 1/20 0.32
HCRTR2 O43614 1/20 0.32
TP53 P04637 1/20 0.32
TDP1 Q9NUW8 1/20 0.32
MALT1 Q9UDY8 2/20 0.32
SCN10A Q9Y5Y9 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2701142 1.00 JAK2 (0.33) JAK2JAK1TYK2JAK3MAPT
SCHEMBL3692653 1.00 JAK2 (0.33) JAK2JAK1TYK2JAK3MAPT
SCHEMBL3707020 1.00 JAK2 (0.33) JAK2JAK1TYK2JAK3MAPT
SCHEMBL2700827 1.00 JAK2 (0.33) JAK2JAK1TYK2JAK3MAPT
SCHEMBL3692645 1.00 JAK2 (0.33) JAK2JAK1TYK2JAK3MAPT
SCHEMBL4570187 0.93 MAPT (0.33) JAK2JAK1TYK2JAK3MAPT
SCHEMBL17082154 0.93 MAPT (0.33) JAK2JAK1TYK2JAK3MAPT
SCHEMBL17082149 0.93 MAPT (0.33) JAK2JAK1TYK2JAK3MAPT
SCHEMBL4570223 0.93 MAPT (0.33) JAK2JAK1TYK2JAK3MAPT
SCHEMBL4570222 0.91 ALDH1A1 (0.35) MAPTOPRK1PDE5AHCRTR1HCRTR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2450351-A1 Lactam compounds and their use as pharmaceuticals Incyte Corporation (US) 2012-05-09 EP claimed
US-20060116382-A1 Lactam compounds and their use as pharmaceuticals INCYTE CORPORATION 2006-06-01 US claimed
EP-2450351-A1 Lactam compounds and their use as pharmaceuticals Incyte Corporation (US) 2012-05-09 EP disclosed
EP-1812005-A2 LACTAM COMPOUNDS AND THEIR USE AS PHARMACEUTICALS Incyte Corporation (US) 2007-08-01 EP disclosed
US-20060116382-A1 Lactam compounds and their use as pharmaceuticals INCYTE CORPORATION 2006-06-01 US disclosed
WO-2006053024-A2 LACTAM COMPOUNDS AND THEIR USE AS PHARMACEUTICALS INCYTE CORPORATION (US) 2006-05-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060116382-A1 Lactam compounds and their use as pharmaceuticals HSD11B1, HSD11B2, HSD17B1 JAK2 4287/4885JAK1 3562/4885TYK2 4824/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.